This company has shut down. CinCor Pharma is no longer operating — its last tracked round was a Post-IPO Equity in 2022.
Explore the Startup GraveyardCinCor is a clinical-stage biopharmaceutical company that develops treatments for cardiovascular diseases.
CinCor Pharma has raised $225.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in August 2022.
CinCor Pharma's investors include General Atlantic, Lilly Asia Ventures, Adage Capital Management, Perceptive Advisors, Sofinnova Partners.
CinCor Pharma is headquartered in Cincinnati, United States.
CinCor is a clinical-stage biopharmaceutical company that develops treatments for cardiovascular diseases.
CinCor Pharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CinCor Pharma — Funding & Investors." VCBacked, August 11, 2022, https://www.vcbacked.co/company/cincor-pharma. Accessed August 1, 2026.
VCBacked. (2022). CinCor Pharma — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/cincor-pharma
{{cite web |title=CinCor Pharma — Funding & Investors |url=https://www.vcbacked.co/company/cincor-pharma |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated